NextCure (NXTC) News Today $1.30 -0.01 (-0.76%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNovember 19 at 8:05 AM | globenewswire.comNextCure Reports Improved Financial Performance and Strategic FocusNovember 12, 2024 | markets.businessinsider.comNextCure’s Strategic Shift and Financial Stability Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comNextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comNextCure reports data from LNCB74, NC410 studiesNovember 7, 2024 | markets.businessinsider.comNextCure (NXTC) Earnings Dates & ReportsNovember 5, 2024 | investing.comNextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingNovember 5, 2024 | globenewswire.comNextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | markets.businessinsider.comNextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | globenewswire.comNextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024September 16, 2024 | globenewswire.comIs NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?September 4, 2024 | finance.yahoo.comBuy Rating for NextCure Supported by Promising Clinical Results and Strong Financial PositionAugust 3, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on NextCure (NXTC)August 3, 2024 | markets.businessinsider.comNextCure Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 1, 2024 | stockhouse.comNextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceJune 20, 2024 | globenewswire.comNextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024May 30, 2024 | globenewswire.comNextCure, Inc. (NXTC)May 29, 2024 | finance.yahoo.comBuy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid FinancialsMay 4, 2024 | markets.businessinsider.comNXTC Stock Earnings: NextCure Misses EPS for Q1 2024May 2, 2024 | investorplace.comNextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024April 24, 2024 | globenewswire.comPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy RatingApril 8, 2024 | markets.businessinsider.comNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024April 8, 2024 | globenewswire.comNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardApril 4, 2024 | globenewswire.comNextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | globenewswire.comNextCure, Inc. (NASDAQ:NXTC) Short Interest UpdateNextCure, Inc. (NASDAQ:NXTC - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 839,700 shares, a growth of 579.9% from the February 29th total of 123,500 shares. Based on an average daily trading volume, of 229,500 shares, the short-interest ratio is presently 3.7 days. Approximately 4.0% of the company's stock are sold short.March 27, 2024 | marketbeat.comWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?March 27, 2024 | finance.yahoo.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 23, 2024 | investorplace.comPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy RatingMarch 22, 2024 | markets.businessinsider.comHC Wainwright Boosts NextCure (NASDAQ:NXTC) Price Target to $8.00HC Wainwright boosted their price target on NextCure from $5.00 to $8.00 and gave the company a "buy" rating in a research note on Friday.March 22, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)March 21, 2024 | markets.businessinsider.comNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug CandidatesMarch 21, 2024 | marketwatch.comMd. biopharma lays off staff, pauses manufacturing to preserve cashMarch 21, 2024 | bizjournals.comNextCure Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 21, 2024 | globenewswire.comNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesMarch 5, 2024 | globenewswire.comNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersJanuary 18, 2024 | finance.yahoo.comNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and DatesDecember 28, 2023 | benzinga.comHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom FishingDecember 25, 2023 | finance.yahoo.comNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryDecember 21, 2023 | finance.yahoo.comNextCure (NXTC) Down on Shelving Plans to Develop CandidateDecember 15, 2023 | finance.yahoo.comBuy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline ShiftDecember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)December 15, 2023 | markets.businessinsider.comNextCure stock falls 20% amid program shutdown, business updateDecember 14, 2023 | msn.comNextCure Shares Fall 26% After Halting Development of One Drug CandidateDecember 14, 2023 | marketwatch.comNextCure Provides Year-End Clinical Pipeline UpdatesDecember 14, 2023 | finance.yahoo.comNextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 20, 2023 | finance.yahoo.comNextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNovember 15, 2023 | finance.yahoo.comNextCure Inc NXTCNovember 12, 2023 | morningstar.comAll You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to BuyNovember 7, 2023 | msn.comNextCure Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.com Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin NXTC Media Mentions By Week NXTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NXTC News Sentiment▼0.000.46▲Average Medical News Sentiment NXTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NXTC Articles This Week▼10▲NXTC Articles Average Week Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HOOK News Today KZR News Today FTLF News Today DRUG News Today IVA News Today ABOS News Today BDTX News Today IXHL News Today SGMT News Today CRDL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NXTC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NXTC Stock Alerts